Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Cerny

Showing results (61-70 of 80) with videos related to

Pageof 8
Sort By:
Forschende Komplementarmedizin (2006)|July 27, 2006
Palliative in-patient cancer treatment in an anthroposophic hospital: II. Quality of life during and after stationary treatment, and subjective treatment benefitsPeter Heusser, Sarah Berger Braun, Manuel Bertschy, et al.
Annals of Surgical Oncology|August 3, 2013
Relative survival is an adequate estimate of cancer-specific survival: baseline mortality-adjusted 10-year survival of 771 rectal cancer patientsIgnazio Tarantino, Philipp Achermann, Ulrich Güller, et al.
British Journal of Clinical Pharmacology|August 16, 2011
Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexateMarkus Joerger, Andrés J M Ferreri, Stephan Krähenbühl, et al.
Acta Haematologica|November 11, 2006
The multicenter trial SAKK 37/95 of cladribine, cyclophosphamide and prednisone in the treatment of chronic lymphocytic leukemias and low-grade non-Hodgkin's lymphomasFrance Laurencet, Pierluigi Ballabeni, Beatrice Rufener, et al.
European Journal of Cancer (Oxford, England : 1990)|March 15, 2005
Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC studyAlain Ravaud, Thomas Cerny, Catherine Terret, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2006
Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group, Florian Strasser, Diana Luftner, et al.
Leukemia & Lymphoma|April 15, 2003
HIV-testing and newly-diagnosed malignant lymphomas. The SAKK 96/90 registration studyGiannicola D'Addario, Alexander Dieterle, Joachim Torhorst, et al.
European Urology|July 12, 2011
Novel prognostic markers in the serum of patients with castration-resistant prostate cancer derived from quantitative analysis of the pten conditional knockout mouse proteomeMartin Kälin, Igor Cima, Ralph Schiess, et al.
Cancer Chemotherapy and Pharmacology|July 30, 2005
A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinomaMonika Jermann, Rolf A Stahel, Marc Salzberg, et al.
Cancer Immunology, Immunotherapy : CII|April 14, 2006
Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinomaYing Waeckerle-Men, Edith Uetz-von Allmen, Markus Fopp, et al.
Pageof 8

Showing results (61-70 of 80) with videos related to

Sort By:
Pageof 8
Forschende Komplementarmedizin (2006)|July 27, 2006
Palliative in-patient cancer treatment in an anthroposophic hospital: II. Quality of life during and after stationary treatment, and subjective treatment benefitsPeter Heusser, Sarah Berger Braun, Manuel Bertschy, et al.
Annals of Surgical Oncology|August 3, 2013
Relative survival is an adequate estimate of cancer-specific survival: baseline mortality-adjusted 10-year survival of 771 rectal cancer patientsIgnazio Tarantino, Philipp Achermann, Ulrich Güller, et al.
British Journal of Clinical Pharmacology|August 16, 2011
Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexateMarkus Joerger, Andrés J M Ferreri, Stephan Krähenbühl, et al.
Acta Haematologica|November 11, 2006
The multicenter trial SAKK 37/95 of cladribine, cyclophosphamide and prednisone in the treatment of chronic lymphocytic leukemias and low-grade non-Hodgkin's lymphomasFrance Laurencet, Pierluigi Ballabeni, Beatrice Rufener, et al.
European Journal of Cancer (Oxford, England : 1990)|March 15, 2005
Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC studyAlain Ravaud, Thomas Cerny, Catherine Terret, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2006
Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group, Florian Strasser, Diana Luftner, et al.
Leukemia & Lymphoma|April 15, 2003
HIV-testing and newly-diagnosed malignant lymphomas. The SAKK 96/90 registration studyGiannicola D'Addario, Alexander Dieterle, Joachim Torhorst, et al.
European Urology|July 12, 2011
Novel prognostic markers in the serum of patients with castration-resistant prostate cancer derived from quantitative analysis of the pten conditional knockout mouse proteomeMartin Kälin, Igor Cima, Ralph Schiess, et al.
Cancer Chemotherapy and Pharmacology|July 30, 2005
A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinomaMonika Jermann, Rolf A Stahel, Marc Salzberg, et al.
Cancer Immunology, Immunotherapy : CII|April 14, 2006
Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinomaYing Waeckerle-Men, Edith Uetz-von Allmen, Markus Fopp, et al.
Pageof 8